Condition
Neuroendocrine Carcinomas (NEC)
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (3)
P 4 (1)
Trial Status
Not Yet Recruiting2
Recruiting2
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06893783Phase 2RecruitingPrimary
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
NCT05652686Phase 1Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT07156019Phase 2Not Yet RecruitingPrimary
Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma
NCT07014540Phase 4Not Yet RecruitingPrimary
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
NCT04525638Phase 2Unknown
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Showing all 5 trials